Factors associated with early initiation of disease-modifying drug treatment in newly-diagnosed patients with multiple sclerosis

Current Medical Research and Opinion
Natalie C EdwardsAmy L Phillips

Abstract

To examine the time to first disease-modifying drug (DMD) treatment and to identify factors associated with early DMD initiation in newly-diagnosed patients with MS. This retrospective cohort study included newly-diagnosed patients with MS from a US administrative claims database, aged 18-65 years, with a first MS diagnosis (ICD-9-CM code: 340.xx) between January 1, 2007 and June 30, 2013 (index date), continuous eligibility for 12 months pre- and 24 months post-index, and initiated DMD treatment within 2 years. Time to first DMD within 24 months post-index was evaluated. A logistic regression model predicted earlier initiation of DMD treatment (within 60 days of MS diagnosis). In total, 37.4% of patients initiated DMD treatment within 2 years of MS diagnosis and were included in the primary analysis (n = 7,124). Mean (standard deviation [SD]) time from MS diagnosis to first DMD was 112.6 (148.3) days (median = 51); 30.7% received first DMD in <30 days, 55.1% in <60 days, and 18.5% not until ≥180 days after diagnosis. Logistic regression found that younger age; not living in the Northeast; diagnoses of balance disorders, numbness, and optical neuritis; the absence of musculoskeletal diagnoses; and a neurologist visit or MRI wit...Continue Reading

References

Jun 1, 1992·Journal of Clinical Epidemiology·R A DeyoM A Ciol
Apr 17, 2002·Lancet·Alastair Compston, Alasdair Coles
Jun 13, 2006·Multiple Sclerosis : Clinical and Laboratory Research·C C FordUNKNOWN Copaxone Study Group
Nov 12, 2010·Journal of Managed Care Pharmacy : JMCP·Carl V AscheAaron Miller
Aug 29, 2012·Acta Neurologica Scandinavica·N GryttenR C Haugstad
Apr 23, 2013·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Mark S FreedmanUNKNOWN Canadian Multiple Sclerosis Working Group
May 7, 2013·Neurología : publicación oficial de la Sociedad Española de Neurología·A García-MerinoUNKNOWN Grupo de Consenso de la Sociedad Española de Neurología
Jan 24, 2014·International Journal of MS Care·Ilya KisterJoseph Herbert
Feb 18, 2014·Journal of Neurology, Neurosurgery, and Psychiatry·Helmut ButzkuevenUNKNOWN TYSABRI Observational Program (TOP) Investigators
May 23, 2014·Journal of Neurology, Neurosurgery, and Psychiatry·Orla TuohyAlasdair Coles
Nov 30, 2014·Multiple Sclerosis : Clinical and Laboratory Research·Bernd C KieseierPeter A Calabresi
Jun 27, 2015·Journal of Neurology, Neurosurgery, and Psychiatry·Jeffrey A CohenUNKNOWN TRANSFORMS (TRial Assessing injectable interferoN vS. FTY720 Oral in RRMS) Study Group
Aug 8, 2015·Nature Reviews. Immunology·Calliope A DendrouManuel A Friese
Sep 17, 2015·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·N GrigoriadisUNKNOWN ParadigMS Group
Nov 14, 2015·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·Ø TorkildsenL Bø
Nov 28, 2015·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Pierre DuquetteRobyn Schecter
Feb 19, 2016·Neurology·Piyameth DilokthornsakulJonathan D Campbell
Mar 6, 2016·Neurology·Tingting ZhangUNKNOWN CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis
May 22, 2016·Multiple Sclerosis : Clinical and Laboratory Research·Ralf GoldTheodore J Phillips

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.